BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

373 related articles for article (PubMed ID: 34429326)

  • 1. mTORC1 Promotes ARID1A Degradation and Oncogenic Chromatin Remodeling in Hepatocellular Carcinoma.
    Zhang S; Zhou YF; Cao J; Burley SK; Wang HY; Zheng XFS
    Cancer Res; 2021 Nov; 81(22):5652-5665. PubMed ID: 34429326
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enhanced SMARCD1, a subunit of the SWI/SNF complex, promotes liver cancer growth through the mTOR pathway.
    Zhou Y; Xu Q; Tao L; Chen Y; Shu Y; Wu Z; Lu C; Shi Y; Bu H
    Clin Sci (Lond); 2020 Jun; 134(12):1457-1472. PubMed ID: 32514535
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Arid1a Has Context-Dependent Oncogenic and Tumor Suppressor Functions in Liver Cancer.
    Sun X; Wang SC; Wei Y; Luo X; Jia Y; Li L; Gopal P; Zhu M; Nassour I; Chuang JC; Maples T; Celen C; Nguyen LH; Wu L; Fu S; Li W; Hui L; Tian F; Ji Y; Zhang S; Sorouri M; Hwang TH; Letzig L; James L; Wang Z; Yopp AC; Singal AG; Zhu H
    Cancer Cell; 2017 Nov; 32(5):574-589.e6. PubMed ID: 29136504
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ARID1A Hypermethylation Disrupts Transcriptional Homeostasis to Promote Squamous Cell Carcinoma Progression.
    Luo Q; Wu X; Chang W; Zhao P; Zhu X; Chen H; Nan Y; Luo A; Zhou X; Su D; Jiao W; Liu Z
    Cancer Res; 2020 Feb; 80(3):406-417. PubMed ID: 32015157
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Loss of ARID1A Promotes Epithelial-Mesenchymal Transition and Sensitizes Pancreatic Tumors to Proteotoxic Stress.
    Tomihara H; Carbone F; Perelli L; Huang JK; Soeung M; Rose JL; Robinson FS; Lissanu Deribe Y; Feng N; Takeda M; Inoue A; Poggetto ED; Deem AK; Maitra A; Msaouel P; Tannir NM; Draetta GF; Viale A; Heffernan TP; Bristow CA; Carugo A; Genovese G
    Cancer Res; 2021 Jan; 81(2):332-343. PubMed ID: 33158812
    [TBL] [Abstract][Full Text] [Related]  

  • 6. mTOR regulates aerobic glycolysis through NEAT1 and nuclear paraspeckle-mediated mechanism in hepatocellular carcinoma.
    Zhang H; Su X; Burley SK; Zheng XFS
    Theranostics; 2022; 12(7):3518-3533. PubMed ID: 35547764
    [No Abstract]   [Full Text] [Related]  

  • 7. Fbxw7 is an independent prognostic marker and induces apoptosis and growth arrest by regulating YAP abundance in hepatocellular carcinoma.
    Tu K; Yang W; Li C; Zheng X; Lu Z; Guo C; Yao Y; Liu Q
    Mol Cancer; 2014 May; 13():110. PubMed ID: 24884509
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The SWI/SNF complex is a mechanoregulated inhibitor of YAP and TAZ.
    Chang L; Azzolin L; Di Biagio D; Zanconato F; Battilana G; Lucon Xiccato R; Aragona M; Giulitti S; Panciera T; Gandin A; Sigismondo G; Krijgsveld J; Fassan M; Brusatin G; Cordenonsi M; Piccolo S
    Nature; 2018 Nov; 563(7730):265-269. PubMed ID: 30401838
    [TBL] [Abstract][Full Text] [Related]  

  • 9. FSTL1 Secreted by Activated Fibroblasts Promotes Hepatocellular Carcinoma Metastasis and Stemness.
    Loh JJ; Li TW; Zhou L; Wong TL; Liu X; Ma VWS; Lo CM; Man K; Lee TK; Ning W; Tong M; Ma S
    Cancer Res; 2021 Nov; 81(22):5692-5705. PubMed ID: 34551961
    [TBL] [Abstract][Full Text] [Related]  

  • 10. mTORC1 Up-Regulates GP73 to Promote Proliferation and Migration of Hepatocellular Carcinoma Cells and Growth of Xenograft Tumors in Mice.
    Chen X; Wang Y; Tao J; Shi Y; Gai X; Huang F; Ma Q; Zhou Z; Chen H; Zhang H; Liu Z; Sun Q; Peng H; Chen R; Jing Y; Yang H; Mao Y; Zhang H
    Gastroenterology; 2015 Sep; 149(3):741-52.e14. PubMed ID: 25980751
    [TBL] [Abstract][Full Text] [Related]  

  • 11. BUB1B promotes hepatocellular carcinoma progression via activation of the mTORC1 signaling pathway.
    Qiu J; Zhang S; Wang P; Wang H; Sha B; Peng H; Ju Z; Rao J; Lu L
    Cancer Med; 2020 Nov; 9(21):8159-8172. PubMed ID: 32977361
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Arid1a regulates response to anti-angiogenic therapy in advanced hepatocellular carcinoma.
    Hu C; Li W; Tian F; Jiang K; Liu X; Cen J; He Q; Qiu Z; Kienast Y; Wang Z; Zhang H; Ji Y; Hu J; Hui L
    J Hepatol; 2018 Mar; 68(3):465-475. PubMed ID: 29113912
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MicroRNA-27b exerts an oncogenic function by targeting Fbxw7 in human hepatocellular carcinoma.
    Sun XF; Sun JP; Hou HT; Li K; Liu X; Ge QX
    Tumour Biol; 2016 Nov; 37(11):15325-15332. PubMed ID: 27704356
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hippocalcin-Like 1 blunts liver lipid metabolism to suppress tumorigenesis via directly targeting RUVBL1-mTOR signaling.
    Chen T; Yuan Z; Lei Z; Duan J; Xue J; Lu T; Yan G; Zhang L; Liu Y; Li Q; Zhang Y
    Theranostics; 2022; 12(17):7450-7464. PubMed ID: 36438486
    [No Abstract]   [Full Text] [Related]  

  • 15. Inhibition of mTORC2 Induces Cell-Cycle Arrest and Enhances the Cytotoxicity of Doxorubicin by Suppressing MDR1 Expression in HCC Cells.
    Chen BW; Chen W; Liang H; Liu H; Liang C; Zhi X; Hu LQ; Yu XZ; Wei T; Ma T; Xue F; Zheng L; Zhao B; Feng XH; Bai XL; Liang TB
    Mol Cancer Ther; 2015 Aug; 14(8):1805-15. PubMed ID: 26026051
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ARID1A represses hepatocellular carcinoma cell proliferation and migration through lncRNA MVIH.
    Cheng S; Wang L; Deng CH; Du SC; Han ZG
    Biochem Biophys Res Commun; 2017 Sep; 491(1):178-182. PubMed ID: 28716731
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MEIS2C and MEIS2D promote tumor progression via Wnt/β-catenin and hippo/YAP signaling in hepatocellular carcinoma.
    Guan L; Li T; Ai N; Wang W; He B; Bai Y; Yu Z; Li M; Dong S; Zhu Q; Ding XX; Zhang S; Li M; Tang G; Xia X; Zhao J; Lin S; Yao S; Zhang L; Chen G; Liu FE; Li X; Zhang H
    J Exp Clin Cancer Res; 2019 Oct; 38(1):417. PubMed ID: 31623651
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CXCL14 inhibits the growth and promotes apoptosis of hepatocellular carcinoma cells via suppressing Akt/mTOR pathway.
    Bi J; Liu Q; Sun Y; Hu X; He X; Xu C
    J Recept Signal Transduct Res; 2021 Dec; 41(6):593-603. PubMed ID: 33108937
    [TBL] [Abstract][Full Text] [Related]  

  • 19. p53 haploinsufficiency and increased mTOR signalling define a subset of aggressive hepatocellular carcinoma.
    Luo YD; Fang L; Yu HQ; Zhang J; Lin XT; Liu XY; Wu D; Li GX; Huang D; Zhang YJ; Chen S; Jiang Y; Shuai L; He Y; Zhang LD; Bie P; Xie CM
    J Hepatol; 2021 Jan; 74(1):96-108. PubMed ID: 32738450
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The roles of mutated SWI/SNF complexes in the initiation and development of hepatocellular carcinoma and its regulatory effect on the immune system: A review.
    Hu B; Lin JZ; Yang XB; Sang XT
    Cell Prolif; 2020 Apr; 53(4):e12791. PubMed ID: 32162380
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.